cancer immunotherapy
cancer immunotherapy
Revolutionary Munich Company Doses First Patient with Groundbreaking Cancer Treatment
BIOT
📢 Tubulis from Munich doses first patient with its ADC candidate TUB-040 targeting NaPi2b antigen in ovarian and lung cancer. 🧪
Game-Changing Cancer Immunotherapy Deal Unveiled
BIOT
📰 Domain Therapeutics and Chime Biologics join forces to develop an anti-CCR8 antibody for cancer immunotherapy! 👥💉 Exciting times ahead! 🤝
